Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia

Schizophrenia Bulletin

Volumn 38, Issue 3, 2012, Pages 426-432

  Linderholm, Klas R ^a   Skogh, Elisabeth ^b   Olsson, Sara K ^a   Dahl, Marja Liisa ^c,d   Holtze, Maria ^a   Engberg, Göran ^a   Samuelsson, Martin ^b   Erhardt, Sophie ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

cerebrospinal fluid; kynurenate; olanzapine; psychosis; tryptophan

Indexed keywords

KYNURENIC ACID; KYNURENINE; OLANZAPINE; TRYPTOPHAN;

ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; LUMBAR PUNCTURE; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; HUMANS; KYNURENIC ACID; KYNURENINE; MALE; MIDDLE AGED; SCHIZOPHRENIA; TRYPTOPHAN; UP-REGULATION; YOUNG ADULT;

EID: 84860159640     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbq086     Document Type: Article

References (58)

1. Erhardt S, Blennow K, Nordin C, Skogh E, Lindstrom LH, Engberg G. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett. 2001;313:96-98. (Pubitemid 32973903)
2. Nilsson LK, Linderholm KR, Engberg G, et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res. 2005;80:315-322. (Pubitemid 41713657)
3. Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry. 2001;50:521-530. (Pubitemid 32971883)
4. Parsons CG, Danysz W, Quack G, et al. Novel systemically active antagonists of the glycine site of the N-methyl-Daspartate receptor: electrophysiological, biochemical and behavioral characterization. J Pharmacol Exp Ther. 1997;283: 1264-1275. (Pubitemid 28016502)
5. Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci. 2001;21:7463-7473. (Pubitemid 32904945)
6. Javitt DC. Glutamate and schizophrenia: phencyclidine, Nmethyl-d-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol. 2007;78:69-108.
7. Albuquerque EX, Pereira EF, Alkondon M, Rogers SW. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev. 2009;89:73-120.
8. Chess AC, Bucci DJ. Increased concentration of cerebral kynurenic acid alters stimulus processing and conditioned responding. Behav Brain Res. 2006;170:326-332. (Pubitemid 44255505)
9. Chess AC, Simoni MK, Alling TE, Bucci DJ. Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr Bull. 2007;33:797-804. (Pubitemid 47343705)
10. Chess AC, Landers AM, Bucci DJ. L-kynurenine treatment alters contextual fear conditioning and context discrimination but not cue-specific fear conditioning. Behav Brain Res. 2009; 201:325-331.
11. Erhardt S, Schwieler L, Emanuelsson C, Geyer M. Endogenous kynurenic acid disrupts prepulse inhibition. Biol Psychiatry. 2004;56:255-260. (Pubitemid 39092940)
12. Braff DL, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl). 2001;156:234-258. (Pubitemid 32705488)
13. Braff D, Stone C, Callaway E, Geyer M, Glick I, Bali L. Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology. 1978;15:339-343. (Pubitemid 9016401)
14. Waters FA, Maybery MT, Badcock JC, Michie PT. Context memory and binding in schizophrenia. Schizophr Res. 2004; 68:119-125. (Pubitemid 38526136)
15. Brebion G, David AS, Jones HM, Ohlsen R, Pilowsky LS. Temporal context discrimination in patients with schizophrenia: associations with auditory hallucinations and negative symptoms. Neuropsychologia. 2007;45:817-823. (Pubitemid 44958756)
16. Moroni F, Russi P, Lombardi G, Beni M, Carla V. Presence of kynurenic acid in the mammalian brain. J Neurochem. 1988;51:177-180.
17. Turski WA, Nakamura M, Todd WP, Carpenter BK, Whetsell WO, Jr, Schwarcz R. Identification and quantification of kynurenic acid in human brain tissue. Brain Res. 1988;454:164-169.
18. Amori L, Wu HQ, Marinozzi M, Pellicciari R, Guidetti P, Schwarcz R. Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum. Neuroscience. 2009;159:196-203.
19. Rassoulpour A, Wu HQ, Ferre S, Schwarcz R. Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. J Neurochem. 2005;93:762-765. (Pubitemid 40617635)
20. Sapko MT, Guidetti P, Yu P, Tagle DA, Pellicciari R, Schwarcz R. Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: implications for Huntington's disease. Exp Neurol. 2006;197:31-40. (Pubitemid 41817219)
21. Shepard PD, Joy B, Clerkin L, Schwarcz R. Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. Neuropsychopharmacology. 2003;28:1454-1462. (Pubitemid 41070880)
22. Erhardt S, Olsson SK, Engberg G. Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders. CNS Drugs. 2009;23:91-101.
23. Wu HQ, Pereira EF, Bruno JP, Pellicciari R, Albuquerque EX, Schwarcz R. The astrocyte-derived alpha7 nicotinic receptor antagonist kynurenic acid controls extracellular glutamate levels in the prefrontal cortex. J Mol Neurosci. 2010;40: 204-210.
24. Araque A, Parpura V, Sanzgiri RP, Haydon PG. Tripartite synapses: glia, the unacknowledged partner. Trends Neurosci. 1999;22:208-215. (Pubitemid 29202082)
25. Erhardt S, Oberg H, Mathe JM, Engberg G. Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons. Amino Acids. 2001;20:353-362. (Pubitemid 32523118)
26. Erhardt S, Engberg G. Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid. Acta Physiol Scand. 2002;175:45-53. (Pubitemid 34534004)
27. Nilsson LK, Linderholm KR, Erhardt S. Subchronic treatment with kynurenine and probenecid: effects on prepulse inhibition and firing of midbrain dopamine neurons. J Neural Transm. 2006;113:557-571. (Pubitemid 43673596)
28. Schwieler L, Erhardt S, Nilsson L, Linderholm K, Engberg G. Effects of COX-1 and COX-2 inhibitors on the firing of rat midbrain dopaminergic neurons-possible involvement of endogenous kynurenic acid. Synapse. 2006; 59:290-298. (Pubitemid 43271737)
29. Schwieler L, Linderholm KR, Nilsson-Todd LK, Erhardt S, Engberg G. Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area. Life Sci. 2008; 83:170-175.
30. Linderholm KR, Andersson A, Olsson S, et al. Activation of rat ventral tegmental area dopamine neurons by endogenous kynurenic acid: a pharmacological analysis. Neuropharmacology. 2007;53:918-924. (Pubitemid 350137391)
31. Olsson SK, Andersson AS, Linderholm KR, et al. Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: implications for schizophrenia. Int J Neuropsychopharmacol. 2009;12:501-512.
32. Zmarowski A, Wu HQ, Brooks JM, et al. Astrocyte-derived kynurenic acid modulates basal and evoked cortical acetylcholine release. Eur J Neurosci. 2009;29:529-538.
33. Erhardt S, Oberg H, Engberg G. Pharmacologically elevated levels of endogenous kynurenic acid prevent nicotine-induced activation of nigral dopamine neurons. Naunyn Schmiedebergs Arch Pharmacol. 2001;363:21-27. (Pubitemid 32060083)
34. Schwieler L, Erhardt S. Inhibitory action of clozapine on rat ventral tegmental area dopamine neurons following increased levels of endogenous kynurenic acid. Neuropsychopharmacology. 2003;28:1770-1777. (Pubitemid 41070842)
35. Potter MC, Elmer GI, Bergeron R, et al. Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology. 2010;35:1734-1742.
36. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull. 1988;24:97-99.
37. American Psychiatric Association. DSM-IV Options Book: Work in Progress.Washington, DC: American Psychiatric Association; 1991.
38. First MB, Spitzer RI, Gibbon M, Williams JBW. Structured Clinical Interview for DMS-IV Axis I Disorders (SCIDI)-Clinician Version. Washington, DC: American Psychiatric Press; 1997.
39. First MB, Spitzer RI, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II). Washington, DC: American Psychiatric Press; 1997.
40. Olsson S, Samuelsson M, Saetre P. Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder. J Psychiatry Neurosci. 2010;35:195-199.
41. Olsson SK, Samuelsson M, Saetre P, et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder. J Psychiatry Neurosci. 2010;35:195-199.
42. Linderholm KR, Erhardt S, Lindqvist D, et al. Kynurenic Acid in the Cerebrospinal Fluid of Male Suicide Attempters-Increased Levels in Patients with MDD and Correlations with Cytokines. Chicago, IL: Society for Neuroscience; 2009. Program No. 305.5. Neuroscience Meeting Planner. Online Abstract.
43. Ceresoli-Borroni G, Rassoulpour A, Wu HQ, Guidetti P, Schwarcz R. Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain. J Neural Transm. 2006;113:1355-1365. (Pubitemid 44435873)
44. Miller CL, Llenos IC, Dulay JR, Weis S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res. 2006;1073-1074:25-37.
45. Miller CL, Llenos IC, Cwik M, Walkup J, Weis S. Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder. Neurochem Int. 2008;52:1297-1303.
46. Schmidt SK, Muller A, Heseler K, et al. Antimicrobial and immunoregulatory properties of human tryptophan 2, 3-dioxygenase. Eur J Immunol. 2009;39:2755-2764.
47. Asp L, Holtze M, Powell SB, Karlsson H, Erhardt S. Neonatal infection with neurotropic influenza A virus induces the kynurenine pathway in early life and disrupts sensorimotor gating in adult Tap1-/-mice. Int J Neuropsychopharmacol. 2010;13:475-485.
48. Holtze M, Asp L, Schwieler L, Engberg G, Karlsson H. Induction of the kynurenine pathway by neurotropic influenza A virus infection. J Neurosci Res. 2008;86:3674-3683.
49. King NJ, Thomas SR. Molecules in focus: indoleamine 2, 3-dioxygenase. Int J Biochem Cell Biol. 2007;39:2167-2172.
50. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9:46-56. (Pubitemid 350295688)
51. Söderlund J, Schroder J, Nordin C, et al. Activation of brain interleukin-1beta in schizophrenia. Mol Psychiatry. 2009; 14:1069-1071.
52. Miller CL, Llenos IC, Dulay JR, Barillo MM, Yolken RH, Weis S. Expression of the kynurenine pathway enzyme tryptophan 2, 3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol Dis. 2004;15:618-629. (Pubitemid 38429977)
53. Speciale C, Wu HQ, Cini M, Marconi M, Varasi M, Schwarcz R. (R, S)-3, 4-dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats. Eur J Pharmacol. 1996;315:263-267. (Pubitemid 26414271)
54. Erhardt S, Hajos M, Lindberg A, Engberg G. Nicotineinduced excitation of locus coeruleus neurons is blocked by elevated levels of endogenous kynurenic acid. Synapse. 2000;37:104-108. (Pubitemid 30447941)
55. Erhardt S, Engberg G. Excitation of nigral dopamine neurons by the GABA(A) receptor agonist muscimol is mediated via release of glutamate. Life Sci. 2000;67:1901-1911.
56. Holtze M, Saetre P, Erhardt S, et al. Kynurenine 3-monooxygenase polymorphisms in schizophrenia-relevance for kynurenic acid synthesis. 12th Meeting of the International Society for Tryptophan Research; July 9-11, 2009; Florence, Italy. Online Abstract.
57. Sathyasaikumar KV, Stachowski E, Roberts RC, Wonodi I, Thaker G, Schwarcz R. Impairment of kynurenine 3-monooxygenase in the frontal cortex of individuals with schizophrenia: association with the eye tracking endophenotype. Chicago, IL: Society for Neuroscience; 2009. Program No. 747.15. Neuroscience Meeting Planner. Online Abstract.
58. Schwarcz R, Tamminga CA, Kurlan R, Shoulson I. Cerebrospinal fluid levels of quinolinic acid in Huntington's disease and schizophrenia. Ann Neurol. 1988;24:580-582.